CoChat

AVP-786 as a promising treatment option for Alzheimer’s Disease including agitation

Khoury, Rita, Marx, Charlotte, Mirgati, Sidney, Velury, Divya, Chakkamparambil, Binu, Grossberg, George T. · 2021 · Expert Opinion on Pharmacotherapy
Cited by 31

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: To date, there is no FDA-approved treatment for agitation in Alzheimer's disease (AD). Medications currently used off-label have modest clinical efficacy and serious side effects. AREAS COVERED: The authors review the pharmacology, mechanism of action, pharmacokinetics, efficacy, safety and tolerability data of AVP-786, for the treatment of agitation in AD. EXPERT OPINION: AVP-786, the deuterated form of dextromethorphan/quinidine (AVP-923) which is an approved treatment for Pseudo-Bulbar Affect, emerges as a promising and safe treatment for agitation in AD. Deuteration is an innovative technology that accelerates drug development by conducting faster and less costly clinical trials. No phase II trial was conducted with AVP-786 for the treatment of agitation in AD; the decision to expedite the development of this drug was based on a successful phase II study with AVP-923. Phase III trials with AVP-786 (TRIAD-1 and TRIAD-2) showed mixed findings probably due to the difference in study design. Future phase III studies should use innovative study designs such as the Sequential Parallel Comparison Design to mitigate high placebo response, and the Cohen-Mansfield Agitation Inventory for agitation assessment. They should also include positron emission tomography studies to assess occupancy of various receptors in the brain after AVP-786 is administered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/14656566.2021.1882995

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 31

Metadata

Authors
Khoury, R., Marx, C., Mirgati, S., Velury, D., Chakkamparambil, B., & Grossberg, G. T.
Venue
Expert Opinion on Pharmacotherapy
Published
2021-02-26
Volume
22
Issue
7
Pages
783-795
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W3132409525
Cited by
31
References
17
FWCI
3.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AVP-786 as a promising treatment option for Alzheimer’s Disease including agitation. https://app.cochat.ai/papers/10.1080/14656566.2021.1882995
The paper
Khoury, R., Marx, C., Mirgati, S., Velury, D., Chakkamparambil, B., & Grossberg, G. T. (2021). AVP-786 as a promising treatment option for Alzheimer’s Disease including agitation. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2021.1882995

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.